Drugs / UKK0018
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07349212 | Feb 2026 → Mar 2027 expected | anaphylaxis, food allergy | Ukko Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UKK0018 | “UKK0018 is an immunotherapeutic treatment of peanut allergies” NCT07349212 ↗ |
| Modality | Other / unclassified | “UKK0018 is an immunotherapeutic treatment of peanut allergies” NCT07349212 ↗ |
| Route | Other | “The treatment is given by injection” NCT07349212 ↗ |